预约演示
Chutes & Ladders—Madrigal snags Sanofi's Bill Sibold as CEO
2023-09-15
高管变更上市批准优先审批
None
Welcome to this week's Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Max Bayer or Gabrielle Masson, and we will feature it here at the end of each week.
Madrigal snags Sanofi's Bill Sibold as CEO
Madrigal Pharmaceuticals
Madrigal Pharmaceuticalsved as Sanofi’s executive vice president of specialty care and president of North American operations. In those roles, he oversaw 10,000 staffers and grew his operations into the pharma’s largest global business unit. The Big Pharma’s current head of specialty care in North America, Brian Foard, has assumed Sibold’s post while the company searches for a permanent successor.
Sanofirigal, Sibold takes the reins from Paul Friedman, M.D., whoMadrigal Pharmaceuticalstion for seven years. The CEO change-up comes as the organization gears up for a potential FDA green light for lead candidate resmetirom, which would be the first nonalcoholic steatohepatitis treatment to make it to market if approved. The FDA has given resmetirom priority review and expects to make a decision by March 14, 2024. Fierce Biotech
Jazz changes octaves with COO sSanofi
Jazz Pharmaceuticals is singing a new executive tune, after President and Chief Operating Officer Dan Swisher decided to move on from the company. Taking his place is Chief Financial Officer Renée Galá, who’s being fully promoted after joining the company in 2020. She’s previously worked at Theravance, Grail and Lilly.
Jazz Pharmaceuticalsguards comes as Jazz’s pipeline is in the midst of its own transition. Sales of narcolepsy drug Xyrem are being crunched as generics enter the fold, but low-sodium alternative Xywav raked in $327 million in sales in the second quarter. Additional marketed meds Epidiolex and Rylaze each had double-digit growth in the second quarter compared to the same period in 2022.
Jazz Pharmaceuticalson its existing portfolio, Jazz is hunting for additional deals, according to CEO Bruce Cozadd. He told Fierce Biotech in June that the company was on the hunt for deals involving neurology and oncology treatments. Fierce PharmaTheravanceGrailLilly
Flagship Pioneering
Some four months ago, Amanda Kay was hired as Flagshipt of new Flagship spinout Metaphore Biotechnologies. Now, she’s taking on a significantly larger role, leading business development for the whole firm as chief business development partner. She’s also being promoted from operating partner to senior partner. A spokesperson confirmed that she’s relinquished her role at Metaphore as part of move.
Before joining the Flagship ecosystem, Kay was the chief business officer and head of finance at Deep Genomics. She was also the head of corporate development at Synlogic and was the chief operating officer for Pfizer’s inflammation and immunology research units. The CEO of Metaphore, Lovisa Afzelius, Ph.D., overlapped with Kay at Pfizer.
Needless to say, business development is a crucial staple of drug development acMetaphore Biotechnologiesecially at Flagship. Companies like Generate Biomedicines, Moderna and Foghorn, to name a few, all have made considerable licensing and/or research pacts since launching. ReleaseMetaphore
> Sling Therapeutics has tapped Raymond Douglas, M.D., Ph.D., to serve as chief scientific officeDeep Genomicsesearch contributed to the development of Horizon ThSynlogiccs' Tepezza, the first and only FDA-approPfizereatinflammationroid eye disease. ReleaseMetaphorePfizer
> Mitchell Jones, M.D., Ph.D., is joining Palisade Bio as chief medical officer. He previously was the VP of corporate development and strateGenerate BiomedicineseuModernaeleasFoghorn
> Sling Therapeuticso-founder and CEO Evan Stein, M.D., Ph.D., is transitioning out of the top leadership role but taking on CSO and COO duties. ReplaciHorizon TherapeuticsidTepezzaformer CEO of Eiger BioPharmaceuticals. Releasethyroid eye disease
> SpringWorks Therapeutics hopes a new sciPalisade Biof can help propel forward the company’s research ambitions, naming Tai-An Lin, Ph.D., for theChemomab Therapeutics oversaw translational research and discovery biology at Black Diamond Therapeutics. Release
> LIB TherapeuticsPh.D., has been tapped as the new CEO and president of Solu Therapeutics. He most recently was the CEO of Faze Medicines and also sits on the board of AVROBIO. ReleaseEiger BioPharmaceuticals
> SpringWorks Therapeuticselcoming on Minnie Kuo as chief development officer. Before Pliant, Kuo held roles of increasing responsibilities at Vir Biotechnology, most recently serving as SVP of translational and clinical deveBlack Diamond Therapeuticse
> German biotech Repairon has chosen executive chair and co-founder LothaSolu Therapeutics., to helm the company. Germeroth,Faze Medicinesshareholder of Repairon, is a bAVROBIOst and serial biotech entrepreneur. Release
> Pliant Therapeuticshas chosen Stephen Dowd, Ph.D., as its chief business officer. Dowd joins the GPCR company from Rallybio, where he served Vir Biotechnologyss development for European operations, and also has past experience at Kymab (acquired by Sanofi), SNIPR Biome and GSK. Release
> Jacob Jacobsen, Ph.D., is succeeding Joseph Patti, Ph.D., as Evecxia Therapeutics’ president and CEO. Patti has stepped down to pursue other interests, while Jacobsen joins from Duke University and Duke-National University Singapore, where he conducted research. Release
> Confo Therapeuticsringing on Sonia Quaratino, M.D., Ph.D., as EVP and chief medical officer starting in October. Quaratino succeeds Joyson Karakunnel, M.D., and has previously held positions at Georgiamune, Kymab (acquired by SanoKymabNovartis and MSanofieroSNIPR BiomeGaA).GSKlease
> Belgium biotech Augustine Therapeutics is growing its team wiEvecxia Therapeuticsns: Marie Trad, M.D., as chief medical officer; Jonathan van Eyll, Ph.D., as head of pharmacologyDuke Universityyndralewiez as head of nonclinical and early development. Trad is a neurologist and founder of Neuraltra, while von Eyll helped establish UCB Pharma’s translational bioinformatics unit and Szyndralewiez has more than 25 years of drug research and development, most recently from Pherecydes Pharma. Release
> Innate Pharmas tapped Dr. Robert McLeod as VP of clinical development. McLeod joins the U.K. biotech having previously served as Daiichi Sankyo’s senior director and global clinical lead, a reseGeorgiamuneiaKymabCancer ResearcSanofi CeNovartis DrugMerck Serono aMerck KGaA roles at Emergent BioSolutions, Novartis and Chiron. Release
> Biostax’s ImmuneAugustine Therapeuticsy Wilson and President and Director Robert Wilson both resigned July 25, departures that were not due to any dispute or disagreement relating to the company, according to Securities and Exchange Commission documents. The board immediately appointed Immune Therapeutics’ VP Noreen Griffin to seUCB Pharma. ReleasePherecydes Pharma
> Myricx Bioorthopedics company Orthofix has ousted its President and CEO Keith Valentine, Chief Financial Officer John Bostjancic Daiichi Sankyol Officer Patrick Keran after the board of directors “determined thatCancer ResearchCancerof these executives engaged in repeated inappropriate and offensEmergent BioSolutionsatNovartisple cChiron conduct requirements and was inconsistent with the company’s values and culture.” Effective immediately, Orthofix’s board chair Catherine Burzik is taking on the CEO spot. Fierce Medtech
> BiostaxculImmune Therapeutics appointed Uneek Mehra as chief financial and business officer, succeeding August Moretti in his retirement. Mehra joins from Myovant Sciences (acquired by Sumitovant Biopharma), where he also served as CFO and CBO, and also held a senior leadership role at Immune Therapeuticsr companies. Release
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。